Denmark faces significant supply chain disruptions for medical cannabis as STENOCARE warns of uncertainty regarding Bedrocan products from 2027 onwards, due to the gradual phaseout of Dutch exports. The Netherlands has been a primary source of pharmaceutical-grade cannabis for European medical programs. This supply shortage could impact Danish patients relying on cannabis-based treatments for chronic conditions. Healthcare providers and regulatory authorities are now assessing alternative sourcing strategies and domestic cultivation options to ensure continuity of patient access to medical cannabis therapies.
